Fri, Jul 25, 2014, 3:21 AM EDT - U.S. Markets open in 6 hrs 9 mins


% | $
Click the to save as a favorite.

Nektar Therapeutics (NKTR) Message Board

pettitmb 15 posts  |  Last Activity: Jul 18, 2014 3:09 PM Member since: Dec 2, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    About the only biotech without a bounce today...

    by bugsisdog Jul 18, 2014 3:00 PM
    pettitmb pettitmb Jul 18, 2014 3:09 PM Flag

    Agree, trying to be a major leaguer, yet his CEO attributes are more like a Single A player that rides the bench. He just keeps cashing a pay check and printing options.

  • Reply to

    Pettitmb is an NKTR employee.

    by kennedyj69 Jul 18, 2014 1:54 PM
    pettitmb pettitmb Jul 18, 2014 2:44 PM Flag

    Nice try. You are too busy posting scare messages and not looking at my post. I have been long this stock for 8 years added every year, however I am highly critical of HR. In my opinion he has failed the stock holders miserably. He has been CEO for 7 years, nothing approved and valuation lower than when he became CEO. Mishandled 102, cant get trials passed phase 1 or 2 yet promises the moon, then all we hear are crickets. If your intuition on me being an employee is like your stock picking I am feeling a lot better about NKTR stock going up.

  • Reply to

    Jan 7 2007 Compared to today... Thanks HR

    by pettitmb May 9, 2014 11:33 AM
    pettitmb pettitmb Jul 17, 2014 12:24 PM Flag

    What happened? I repeat HR has failed. His execution has been poor in getting drugs through trials. I don't know how this is debatable. I hope the pros can take this technology by a buyout soon.

  • Reply to

    $20 PPS

    by gladpick Jun 19, 2014 10:22 AM
    pettitmb pettitmb Jun 19, 2014 10:32 AM Flag

    That would be in September at the PDUFA. Wait... I mean January 2015 when NKTR releases Phase 3 Results of Beacon. Wait.... I mean when NKTR gets approval of NKTR 102 late 2015. Wait... I mean when Phase 3 results are completed for NKTR 181 in 2016. Wait.... they have not even started Phase 3 on NKTR 181.
    Time value of money has sucked owning this company for over 8 years.

    Ask Corona......Corona will discuss his $4 shares all day long but fails to mention his $14-$21 dollar shares he owns. I don't particularly pay attention to gloaters.

  • pettitmb by pettitmb Jun 15, 2014 10:56 AM Flag

    NKTR made weekend Barron digital edition. Headline.. Two undervalued biopharmas to Buy Now.. Nektar and Progenics. .... Maybe we keep running on Monday.

  • pettitmb pettitmb Jun 13, 2014 10:21 AM Flag

    Volume prediction will be a little off. As a minimum was a safe bet. Hope you are right on price or higher

  • I missed the AZN presentation. Did anyone come away with the same thoughts. AZN was supposedly hitting hard the fact more CV events on Placebo than Movantix (nktr-118)

  • Whatever happened to NKTR-181? Can we not do 2 things at once? The redesign for the Phase 3 trial seems to be sputtering. Is HR waiting to see if he has any cash to spend. Any thoughts from the best board on yahoo?

  • pettitmb by pettitmb Jun 2, 2014 1:12 PM Flag

    If it goes bad... This may be ugly. This is what it is all about in the near term, Not 102 or 214... unless they partner which seems unlikely until after results next February on 102

  • 10 cent above the ask. Look like a short covering

  • He became CEO in January of 2007. The day it was announced the price for NKTR was14.50, they had 90 million shares outstanding 1.3 billion valuation. Today 123 million shares and guess what 1.3 billion valuation. He and his cronies have received many options over the last 7 years on the shareholders back. No one can argue the market was better in 2007 than now for biotechs. This is a complete failure for long term holders of this stock. I truly hope this is the year as HR has told the public.....but every year HR has been CEO, guess what.. .He says this is the year.

  • Reply to

    Groundhog Day

    by pettitmb May 7, 2014 5:48 PM
    pettitmb pettitmb May 7, 2014 9:21 PM Flag

    First and foremost.. more detail on why taken so long. 102 has fast track, 181 has fast track, yet we heard last September on Phase 2 results. Design a phase 3 for 181 and go. What the....? Its like he assumes cash is abundant and he can go anytime to raise money and dilution does not matter. Its time for him to produce or give it to someone that can. HR is milking this. The Board is letting him. Also... explain options if June Adcomm does not go well. WE will begin paying AZN back if it does. Where is the money to do everything he has in his pipeline. They burned 70 million this quarter!!!! He assumes a lot.. I still think the best he has done was get out of Exubera. My opinion it has been down hill from there.

  • Reply to

    $70.0 M of cash burn ?

    by feeling_hijacked May 7, 2014 7:11 PM
    pettitmb pettitmb May 7, 2014 8:57 PM Flag

    If Adcomm goes bad or even pushed out further, we are going to get punished. Worst yet they will need to raise substantial cash as we will have to pay AZN back per our "revised" agreement. We will be in the single digits and yes Very Dilutive....

  • pettitmb by pettitmb May 7, 2014 5:48 PM Flag

    This is beginning to sound like a broken record. Pathetic marketing.. Get rid of the Posion pill so we can be taken out of our misery!

  • As an 8 year holder of this stock, I have mixed feelings about PFE buying AZN. I think there is no love lost between PFE and NKTR. In fact the best thing HR has done since he is been here was get out of Exubera the way he did. On a side point, I think his performance has slide since.... but I digress. PFE would presumably not want 102 to succeed so I see them making life difficult for NKTR if they buy AZN. As AZN is our ATM in the next few years if 118 goes forward and our lien holder if it doesn't. I know this is a tax play but they could get some secondary benefits as well. Maybe I am thinking too much into this but would like to hear other thoughts on this from the board.

11.01+0.01(+0.09%)Jul 24 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.